ClinicalTrials.gg
CompletedNCT01890746Updated Sep 11, 2019Results posted

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

A Phase 2 interventional study of Daunorubicin and Cytarabine in Acute Leukaemia, sponsored by Novartis Pharmaceuticals. Completed at 42 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies in Leukemia by Novartis — 1 open to participants now, 3 under way, 1 of them phase 3. Leukemia · Novartis.

Enrollment
10th of 28
148 · median 105
Started
2013
with 2 others
Phase 2
14 of 35
1 open now
Registered
24th of 35
by date

Among the 35 studies in Leukemia by Novartis, this one is the 10th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2013, is one of 14 in phase 2, and was the 24th registered.

Leukemia

2,382 studies on the registry are indexed under Leukemia; 254 are open to participants now.

Browse Leukemia studies →

Open to participants now

1 of the 35 studies in Leukemia by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 208 Leukemia studies recruiting now, 112 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 86 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Leukemia by Novartis, or all of them as a file.
02

Study summary

The purpose of this randomized, blinded, placebo-controlled study was to provide clinical safety and exploratory efficacy data on the use of Eltrombopag in adult subjects with Acute Myeloid Leukemia (AML) receiving standard induction chemotherapy with daunorubicin plus cytarabine. A minimum of 120 evaluable subjects newly diagnosed with AML was stratified by antecedent malignant hematologic disorder and age.

03

Conditions studied

  • Acute Leukaemia

Keywords

  • AML
  • de novo AML
  • leukemia
  • sAML/MDS
  • acute myeloid leukemia
  • acute myelogenous leukemia (AML)
  • secondary acute myeloid leukemia
  • ETB115
  • Eltrombopag
  • thrombocytopenia
  • oral thrombopoietin receptor agonist
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >=18 years
  • Diagnosed with AML according to the WHO 2008 classification. Note: subjects with secondary AML following Myelodysplastic syndrome or secondary to previous leukemogenic therapy are allowed provided that a record of previous MDS history or leukemogenic therapy history is available.
  • Eligible for induction by daunorubicin + cytarabine.
  • Eligible to give to participate in the study.
  • Have adequate baseline organ function defined by the following criteria:

Total \<=1.5 x (ULN) except for Gilbert's syndrome, or other conditions that are not indicative of inadequate liver function (i.e. elevation of indirect bilirubin (haemolytic) in the absence of [ALT] abnormality).

ALT \<=3 x ULN. Serum Creatinine \<=2.5 x ULN.

  • Adequate cardiac function with >=50% as assessed by echocardiogram (ECHO) or Multi Gated Acquisition Scan (MUGA.
  • Subjects with a corrected for heart rate according to Bazett's formula (QTcB) \<450millisecond (msec) or \<480msec for subjects with bundle branch block. The QTc should be based on single or averaged QTc values of triplicate (ECGs) obtained over a brief recording period.
  • Women must be either of non- or women with child-bearing potential and men with must be willing to practice acceptable methods of during the study.
  • Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from time of randomization until 30 days after the last dose of product.
  • Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception during the study and for 30 days following the last dose of investigational product.

Exclusion criteria

Exclusion Criteria

  • A diagnosis of acute promyelocytic (M3) or acute megakaryocytic leukaemia (M7).
  • Previous history of exposure to an anthracycline compound.
  • Previous AML treatment (other than hydroxyurea).
  • Any serious medical condition, laboratory abnormality, or psychiatric illness that, in the view of the treating physician, would place the participant at an unacceptable risk if he or she were to participate in the study or would prevent that person from giving .
  • History of thromboembolic event or other condition requiring ongoing use of anticoagulation either with warfarin or low molecular-weight heparin. Note: Occlusion of a central line is not exclusion.
  • Treatment with an drug within 30 days or 5 half lives, whichever is longer, preceding the first dose of study medication.
  • Current and continued use during study treatment period of known Breast cancer resistance protein (BCRP) inhibitors or known P-gp inhibitors.
  • Known active , or (HIV) infection.
  • Known to any of the study drugs or its .
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    Eltrombopag arm

    Subjects received induction chemotherapy consisting of daunorubicin bolus intravenous (IV) infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by Eltrombopag once daily orally starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the dose was increased until a platelet count of at least 200 Gi/L was achieved/until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.

    Drug: Daunorubicin · Drug: Cytarabine · Drug: Eltrombopag

  • Placebo comparator
    Placebo arm

    Subject received induction chemotherapy consisting of daunorubicin bolus IV infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by matching placebo once daily oral dose starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the matching placebo was given until a platelet count of at least 200 Gi/L was achieved/ until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received a second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.

    Drug: Daunorubicin · Drug: Cytarabine · Drug: Placebo

Interventions

  • For subjects between the ages of 18 and 60 years, 90 mg/m2/day by bolus IV injection through a freshly established free-flowing IV line for 10-15 minutes on days 1, 2, and 3. For subjects \> 60 years: daunorubicin dose was adjusted to 60mg /m2.

  • 100 mg/m2/day continuous IV infusion on Days 1 through 7.

  • 200 mg orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose of the Investigational Product (IP) was to be increased to 300 mg if platelet counts were \<100 Gi/L. IP continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage 100 mg orally once daily (a 50% dose reduction) was used and after 7 days, the dose of IP was increased to 150 mg if platelet counts were \<100 Gi/L.

  • DrugPlacebo

    Orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose given was matching 300 mg Eltrombopag if platelet counts were \<100 Gi/L. Placebo continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage placebo matching 100 mg Eltrombopag orally once daily was used and after 7 days, the placebo matching 150 mg Eltrombopag was given if platelet counts were \<100 Gi/L.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Adverse Events (AE) and Any Serious Adverse Events (SAE) as a Measure of Safety and Tolerability.

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or is associated with liver injury and impaired liver function.

    Time frame: From the time the first dose of study treatment was administered until 30 days following discontinuation of investigational product regardless of initiation of a new cancer therapy or transfer to hospice

  2. Change From Baseline in the Left Ventricular Ejection Fraction (LVEF).

    LVEF is a measurement of the percentage of blood leaving heart each time it contracts. LVEF was assessed by an echocardiogram (ECHO) or Multiple Gated Acquisition scan (MUGA). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline was calculated as the Day 42 value minus the Baseline value.

    Time frame: Baseline and Day 42 of the latest chemotherapy cycle (Up to 8 weeks)

  3. Number of Participants With Worst-case Grade Changes From Baseline in the Hematology Parameters

    The number of participants with a maximum post-baseline grade increase of Grade 3 (G3) or Grade 4 (G4) from their baseline grade are presented. Hematology parameters included only lab tests that are gradable by Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

    Time frame: Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)

  4. Number of Participants With Worst-case Grade Changes From Baseline in the Clinical Chemistry Parameters

    The number of participants with a maximum post-baseline grade increase of Grade 3 or Grade 4 from their baseline grade are presented. Clinical Clinical Chemistry parameters included only lab tests that are gradable by CTCAE v4.0.

    Time frame: Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)

  5. Number of Participants With Liver Events.

    The number of participants with liver enzyme (ALT, AST, ALP, Total bilirubin) abnormalities while receiving study treatment in each arm are presented.

    Time frame: 8 weeks

  6. Number of Participants With Worst-case Changes From Baseline in Electrocardiogram (ECG) Values

    The number of participants with worst case post-baseline changes (normal, abnormal - not clinically significant \[NCS\], abnormal - clinically significant \[NS\]) in ECG QT prolonged values are presented. The protocol does not define the criteria for normal, abnormal-NCS and abnormal CS ECG. The outcome was based solely on the investigator interpretation of ECG tracings.

    Time frame: Baseline and Day 42 of the latest chemotherapy cycle (Up to 8 weeks)

  7. Number of Participants With Worst-case Changes From Baseline in the Eastern Cooperative Oncology Group (ECOG) Performance Status

    The number of participants with worst case post-baseline changes (improved, no change, deteriorated) are presented.

    Time frame: Baseline and Day 42 of the latest chemotherapy cycle (Up to 8 weeks)

  8. Worst-case Change From Baseline in Pulse Rate Values

    The worst-case post Baseline high and low changes in pulse rate values from Baseline are presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Post Baseline is defined as the highest and lowest non-missing post Baseline value respectively. Change from Baseline was calculated as the post Baseline value minus the Baseline value.

    Time frame: Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)

  9. Worst-case Post Baseline Change in Blood Pressure Values From Baseline

    The worst-case post Baseline high changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) values from Baseline are presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline was calculated as the visit value minus the Baseline value.

    Time frame: Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)

  10. Worst-case Post Baseline Change in Temperature Values From Baseline

    The worst-case post Baseline high and low changes in temperature values from Baseline are presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Post Baseline was defined as the highest and lowest non-missing post Baseline value respectively. Change from Baseline was calculated as the post Baseline value minus the Baseline value.

    Time frame: Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)

Secondary outcomes

  1. Plasma Pharmacokinetics (PK) Parameter of Daunorubicin: Half-life (t1/2)

    Daunorubicin half-life. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

    Time frame: Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)

  2. Plasma Pharmacokinetics (PK) Parameter of Daunorubicinol: Half-life (t1/2)

    Daunorubicinol half-life. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

    Time frame: Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)

  3. Daunorubicin Dose-normalized Plasma: AUC(0-∞)

    Daunorubicin AUC(0-∞). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

    Time frame: Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)

  4. Daunorubicinol Dose-normalized Plasma: AUC(0-∞)

    Daunorubicinol AUC(0-∞). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

    Time frame: Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)

  5. Daunorubicin Dose-normalized Plasma: AUC(24-∞)

    Daunorubicin AUC(24-∞). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

    Time frame: Cycle 1 Day 4 to Day 9 (24 to 144 hrs post-dose)

  6. Daunorubicinol Dose-normalized Plasma: AUC(24-∞)

    Daunorubicinol AUC(24-∞). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

    Time frame: Cycle 1 Day 4 to Day 9 (24 to 144 hrs post-dose)

  7. Daunorubicin Dose-normalized Plasma: AUC(0-t)

    Daunorubicin AUC(0-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

    Time frame: Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)

  8. Daunorubicinol Dose-normalized Plasma: AUC(0-t)

    daunorubicinol AUC(0-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

    Time frame: Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)

  9. Daunorubicin Dose-normalized Plasma: AUC(24-t)

    Daunorubicin AUC(24-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

    Time frame: Cycle 1 Day 4 to Day 9 (24 to 144 hrs post-dose)

  10. Daunorubicinol Dose-normalized Plasma: AUC(24-t)

    Daunorubicinol AUC(24-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

    Time frame: Cycle 1 Day 4 to Day 9 (24 to 144 hrs post-dose)

  11. Daunorubicin Dose-normalized Plasma: Cmax

    Daunorubicin Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

    Time frame: Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)

  12. Daunorubicinol Dose-normalized Plasma: Cmax

    Daunorubicinol Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

    Time frame: Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)

  13. Cycle 2: Daunorubicin Dose-normalized Plasma: AUC(0-24)

    Cycle 2 Daunorubicin AUC(0-24). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

    Time frame: Cycle 2 Day 1 to Day 2 (0 to 24 post-dose)

  14. Cycle 2: Daunorubicinol Dose-normalized Plasma: AUC(0-24)

    Cycle 2 Daunorubicinol AUC(0-24). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

    Time frame: Cycle 2 Day 1 to Day 2 (0 to 24 post-dose)

  15. Cycle 2: Daunorubicin Dose-normalized Plasma: Cmax

    Cycle 2 Daunorubicin Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

    Time frame: Cycle 2 Day 1 to Day 2 (0 to 24 post-dose)

  16. Cycle 2: Daunorubicinol Dose-normalized Plasma: Cmax

    Cycle 2 Daunorubicinol Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

    Time frame: Cycle 2 Day 1 to Day 2 (0 to 24 post-dose)

  17. Number of Platelet Transfusions Per Week Within Cycles

    This was the average number of platelet transfusions per week within cycles.

    Time frame: Post-Base line up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)

  18. Time to Platelet Count Recovery >=20 Gi/L

    Time to Platelet counts \>= 20 Gi/L for 3 consecutive days, unaided by transfusions in patients with \< 20 Gi/L after chemotherapy. For this endpoint, the event required platelet count to be \>= 20 Gi/L for 3 consecutive days. Hematology was assessed daily during hospital stay but only weekly after hospital discharge and thus, platelet count was not always available for 3 consecutive days to confirm the achievement of platelet count recovery.

    Time frame: From last dose of chemotherapy to up to end of study year 2 assessment

  19. Time to Platelet Recovery >=100 Gi/L

    Time to platelet counts \>= 100 Gi/L unaided by transfusions in participants with \< 100 Gi/L after chemotherapy.

    Time frame: From last dose of chemotherapy to up to end of study year 2 assessment

  20. Number of Participants Who Achieved Platelet Count Recovery by Day 21

    Number of participants with platelet counts 20 Gi/L for 3 consecutive days, unaided by transfusions, in patients with \< 20 Gi/L after chemotherapy.

    Time frame: By Day 21

  21. Summary of Platelet Counts Over Time

    Platelet counts over time

    Time frame: Baseline, daily then weekly within cycle up to 42 days after last chemotherapy dose, end of therapy /remission assessment visit

  22. Maximum Duration (Days) of Platelet Transfusion Independence

    Maximum time period (in days) during which the patient did not receive any platelet transfusion

    Time frame: At differnt time points from start of treatment and up to end of study year 2 assessment

  23. Percentage of Patients Who Achieved Platelet Transfusion Independence ≥ 28 Days

    Percentage of patients who achieved platelet transfusion independence ≥ 28 days.

    Time frame: From start of treatment and up to end of study year 2 assessment

  24. Time to Neutrophil Engraftment

    Time to absolute neutrophil count (ANC) \>= 0.5 Gi/L for 3 consecutive days in participants with ANC \< 0.5 Gi/L after chemotherapy

    Time frame: At different time points from last dose of chemotherapy up to end of study year 2 assessment

  25. Summary of Absolute Neutrophil Counts (ANC)

    Absolute neutrophil counts over time

    Time frame: Baseline, daily then weekly within cycle up to 42 days after last chemotherapy dose, end of therapy /remission assessment visit

  26. Summary of Hemoglobin

    Hemoglobin level over time

    Time frame: Baseline, daily then weekly within cycle up to 42 days after last chemotherapy dose, end of therapy /remission assessment visit

  27. Incidence of Hemorrhagic Events

    Incidence of bleeding events using WHO bleeding grade (G0=No bleeding, G1=Petechiae, G2=Mild blood loss, G3=Gross blood loss, G4=Debilitating blood loss) by week and cycle

    Time frame: Baseline, weekly within induction and re-induction cycles, end of therapy

  28. Percentage of Participants With Disease Response Rate and Type of Response

    Disease response as assessed by the investigator using the AML International Working Group Response Assessment at the end of therapy/remission assessment visit; Complete remission (CR): defined as transfusion independence, blood count recovery (Abs. neutrophil count \> 1.0 Gi/L and Platelet count \> 100.0 Gi/L), no leukemic blast in peripheral blood, Bone Marrow (BM) blasts \< 5%, maturation of all cell lines, Auer rods not detectable, and no extramedullary disease. Partial remission (PR): defined as CR except that for BM blasts where a decrease of at least 50% of BM blasts to 5-25% in BM aspirate is sufficient or BM blasts \< 5% with Auer rods present. Overall response (OR) = CR + PR.

    Time frame: Day 42 of the latest chemotherapy cycle (Up to 8 weeks)

  29. Overall Survival (OS)

    Overall survival defined as the time form randomization until the date of death due to any cause.

    Time frame: From randomization to end of 2-year follow-up

  30. Number of Participants Who Required Medical Resource Utilization

    Medical Resource Utilization pertained to unscheduled hospitalizations, unscheduled office visits, unscheduled laboratory tests, and unscheduled procedures.

    Time frame: At screening and from start of treatment to end of therapy/remission assessment visit (Day 42 of the latest chemotherapy cycle)

07

Results

Posted Jun 14, 2016

Participant flow

Participants (Par.) diagnosed with Acute Myelogenous Leukemia (AML) of any subtype (except acute promyelocytic \[M3\] or acute megakaryocytic leukaemia \[M7\]) were eligible for the study.

Participant flow — Overall Study
MilestoneEltrombopag (ELQ) QDPlacebo QD
Started7474
Completed2233
Not completed5241
Withdrew: Death3930
Withdrew: Adverse event10
Withdrew: Lost to follow-up41
Withdrew: Physician decision32
Withdrew: Withdrawal by subject58

Outcome measures

PrimaryNumber of Participants With Any Adverse Events (AE) and Any Serious Adverse Events (SAE) as a Measure of Safety and Tolerability.

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or is associated with liver injury and impaired liver function.

Time frame:
From the time the first dose of study treatment was administered until 30 days following discontinuation of investigational product regardless of initiation of a new cancer therapy or transfer to hospice
Reported as:
Number · Participants
Number of Participants With Any Adverse Events (AE) and Any Serious Adverse Events (SAE) as a Measure of Safety and Tolerability.
ParticipantsEltrombopag (ELQ) QDPlacebo QD
Any AE7266
Any SAE2414
PrimaryChange From Baseline in the Left Ventricular Ejection Fraction (LVEF).

LVEF is a measurement of the percentage of blood leaving heart each time it contracts. LVEF was assessed by an echocardiogram (ECHO) or Multiple Gated Acquisition scan (MUGA). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline was calculated as the Day 42 value minus the Baseline value.

Time frame:
Baseline and Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Reported as:
Mean · LVEF percent
Change From Baseline in the Left Ventricular Ejection Fraction (LVEF).
LVEF percentEltrombopag (ELQ) QDPlacebo QD
chnge from baseline (BL) to end of study-2.5 ± 7.81-4.3 ± 8.54
change from BL to worse post-BL case-4.1 ± 8.61-5.7 ± 9.05
PrimaryNumber of Participants With Worst-case Grade Changes From Baseline in the Hematology Parameters

The number of participants with a maximum post-baseline grade increase of Grade 3 (G3) or Grade 4 (G4) from their baseline grade are presented. Hematology parameters included only lab tests that are gradable by Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

Time frame:
Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Reported as:
Number · Participants
Number of Participants With Worst-case Grade Changes From Baseline in the Hematology Parameters
ParticipantsEltrombopag (ELQ) QDPlacebo QD
Hemoglobin Low, G35346
Leukocytes, G31010
Leukocytes, G495
Lymphocytes Low, G33126
Lymphocytes Low, G43538
Neutrophils, G44439
Platelets, G310
Platelets, G46356
PrimaryNumber of Participants With Worst-case Grade Changes From Baseline in the Clinical Chemistry Parameters

The number of participants with a maximum post-baseline grade increase of Grade 3 or Grade 4 from their baseline grade are presented. Clinical Clinical Chemistry parameters included only lab tests that are gradable by CTCAE v4.0.

Time frame:
Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Reported as:
Number · Participants
Number of Participants With Worst-case Grade Changes From Baseline in the Clinical Chemistry Parameters
ParticipantsEltrombopag (ELQ) QDPlacebo QD
Alanine Aminotransferase, G315
Albumin, G364
Aspartate Aminotransferase, G301
Bilirubin, G314
Bilirubin, G401
Calcium Low, G301
Creatinine, G301
Creatinine, G410
Glucose High, G363
Glucose High, G401
Magnesium Low, G301
Magnesium High, G330
Phosphate, G31019
Phosphate, G410
Potassium Low, G3810
Potassium Low, G402
Potassium High, G340
Potassium High, G411
Sodium Low, G334
Urate, G430
PrimaryNumber of Participants With Liver Events.

The number of participants with liver enzyme (ALT, AST, ALP, Total bilirubin) abnormalities while receiving study treatment in each arm are presented.

Time frame:
8 weeks
Reported as:
Number · Participants
Number of Participants With Liver Events.
ParticipantsEltrombopag (ELQ) QDPlacebo QD
Number of Participants With Liver Events.26
PrimaryNumber of Participants With Worst-case Changes From Baseline in Electrocardiogram (ECG) Values

The number of participants with worst case post-baseline changes (normal, abnormal - not clinically significant \[NCS\], abnormal - clinically significant \[NS\]) in ECG QT prolonged values are presented. The protocol does not define the criteria for normal, abnormal-NCS and abnormal CS ECG. The outcome was based solely on the investigator interpretation of ECG tracings.

Time frame:
Baseline and Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Reported as:
Number · Participants
Number of Participants With Worst-case Changes From Baseline in Electrocardiogram (ECG) Values
ParticipantsEltrombopag (ELQ) QDPlacebo QD
Normal3433
Abnormal - NCS2329
Abnormal - CS21
PrimaryNumber of Participants With Worst-case Changes From Baseline in the Eastern Cooperative Oncology Group (ECOG) Performance Status

The number of participants with worst case post-baseline changes (improved, no change, deteriorated) are presented.

Time frame:
Baseline and Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Reported as:
Number · Participants
Number of Participants With Worst-case Changes From Baseline in the Eastern Cooperative Oncology Group (ECOG) Performance Status
ParticipantsEltrombopag (ELQ) QDPlacebo QD
Deteriorated3636
Improved01
No Change3734
PrimaryWorst-case Change From Baseline in Pulse Rate Values

The worst-case post Baseline high and low changes in pulse rate values from Baseline are presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Post Baseline is defined as the highest and lowest non-missing post Baseline value respectively. Change from Baseline was calculated as the post Baseline value minus the Baseline value.

Time frame:
Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Reported as:
Mean · Beats/minute
Worst-case Change From Baseline in Pulse Rate Values
Beats/minuteEltrombopag (ELQ) QDPlacebo QD
High18.48 ± 20.61617.73 ± 15.112
Low-10.36 ± 14.039-11.24 ± 12.123
PrimaryWorst-case Post Baseline Change in Blood Pressure Values From Baseline

The worst-case post Baseline high changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) values from Baseline are presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline was calculated as the visit value minus the Baseline value.

Time frame:
Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Reported as:
Mean · millimeter of mercury (mmHg)
Worst-case Post Baseline Change in Blood Pressure Values From Baseline
millimeter of mercury (mmHg)Eltrombopag (ELQ) QDPlacebo QD
SBP14.59 ± 17.93614.34 ± 14.626
DBP9.38 ± 12.00012.61 ± 10.947
PrimaryWorst-case Post Baseline Change in Temperature Values From Baseline

The worst-case post Baseline high and low changes in temperature values from Baseline are presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Post Baseline was defined as the highest and lowest non-missing post Baseline value respectively. Change from Baseline was calculated as the post Baseline value minus the Baseline value.

Time frame:
Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Reported as:
Mean · Degrees Celsius
Worst-case Post Baseline Change in Temperature Values From Baseline
Degrees CelsiusEltrombopag (ELQ) QDPlacebo QD
High0.62 ± 0.9410.77 ± 0.879
Low-0.44 ± 0.628-0.63 ± 0.592
SecondaryPlasma Pharmacokinetics (PK) Parameter of Daunorubicin: Half-life (t1/2)

Daunorubicin half-life. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

Time frame:
Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Reported as:
Geometric mean · hour (h)
Plasma Pharmacokinetics (PK) Parameter of Daunorubicin: Half-life (t1/2)
hour (h)Eltrombopag (ELQ) QDPlacebo QD
Plasma Pharmacokinetics (PK) Parameter of Daunorubicin: Half-life (t1/2)15.754 (13.969 to 17.766)13.709 (12.103 to 15.527)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Ratio of geometric means (%): 114.9 · 90% CI 99.5 to 132.7
SecondaryPlasma Pharmacokinetics (PK) Parameter of Daunorubicinol: Half-life (t1/2)

Daunorubicinol half-life. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

Time frame:
Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Reported as:
Geometric mean · hour (h)
Plasma Pharmacokinetics (PK) Parameter of Daunorubicinol: Half-life (t1/2)
hour (h)Eltrombopag (ELQ) QDPlacebo QD
Plasma Pharmacokinetics (PK) Parameter of Daunorubicinol: Half-life (t1/2)22.735 (21.187 to 24.396)21.603 (20.232 to 23.067)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Ratio of geometric means (%): 105.2 · 90% CI 97.1 to 114.0
SecondaryDaunorubicin Dose-normalized Plasma: AUC(0-∞)

Daunorubicin AUC(0-∞). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

Time frame:
Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Reported as:
Geometric mean · (h*ug/ml)/(mg/m2)
Daunorubicin Dose-normalized Plasma: AUC(0-∞)
(h*ug/ml)/(mg/m2)Eltrombopag (ELQ) QDPlacebo QD
Daunorubicin Dose-normalized Plasma: AUC(0-∞)8.0807 (7.0672 to 9.2396)8.7880 (7.3893 to 10.451)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Ratio of geometric means (%): 92.0 · 90% CI 76.8 to 110.2
SecondaryDaunorubicinol Dose-normalized Plasma: AUC(0-∞)

Daunorubicinol AUC(0-∞). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

Time frame:
Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Reported as:
Geometric mean · (h*ug/ml)/(mg/m2)
Daunorubicinol Dose-normalized Plasma: AUC(0-∞)
(h*ug/ml)/(mg/m2)Eltrombopag (ELQ) QDPlacebo QD
Daunorubicinol Dose-normalized Plasma: AUC(0-∞)63.997 (58.686 to 69.746)62.835 (58.673 to 67.292)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Ratio of geometric means (%): 101.8 · 90% CI 92.9 to 111.7
SecondaryDaunorubicin Dose-normalized Plasma: AUC(24-∞)

Daunorubicin AUC(24-∞). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

Time frame:
Cycle 1 Day 4 to Day 9 (24 to 144 hrs post-dose)
Reported as:
Geometric mean · (h*ug/ml)/(mg/m2)
Daunorubicin Dose-normalized Plasma: AUC(24-∞)
(h*ug/ml)/(mg/m2)Eltrombopag (ELQ) QDPlacebo QD
Daunorubicin Dose-normalized Plasma: AUC(24-∞)0.87496 (0.76202 to 1.0046)0.72315 (0.62633 to 0.83493)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Ratio of geometric means (%): 121.0 · 90% CI 102.5 to 142.8
SecondaryDaunorubicinol Dose-normalized Plasma: AUC(24-∞)

Daunorubicinol AUC(24-∞). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

Time frame:
Cycle 1 Day 4 to Day 9 (24 to 144 hrs post-dose)
Reported as:
Geometric mean · (h*ug/ml)/(mg/m2)
Daunorubicinol Dose-normalized Plasma: AUC(24-∞)
(h*ug/ml)/(mg/m2)Eltrombopag (ELQ) QDPlacebo QD
Daunorubicinol Dose-normalized Plasma: AUC(24-∞)24.537 (22.052 to 27.301)23.039 (21.169 to 25.074)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Ratio of geometric means (%): 106.5 · 90% CI 95.0 to 119.4
SecondaryDaunorubicin Dose-normalized Plasma: AUC(0-t)

Daunorubicin AUC(0-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

Time frame:
Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Reported as:
Geometric mean · (h*ug/ml)/(mg/m2)
Daunorubicin Dose-normalized Plasma: AUC(0-t)
(h*ug/ml)/(mg/m2)Eltrombopag (ELQ) QDPlacebo QD
Daunorubicin Dose-normalized Plasma: AUC(0-t)7.9523 (6.9485 to 9.1012)8.6723 (7.2855 to 10.323)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Ratio of geometric means (%): 91.7 · 90% CI 76.5 to 110.0
SecondaryDaunorubicinol Dose-normalized Plasma: AUC(0-t)

daunorubicinol AUC(0-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

Time frame:
Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Reported as:
Geometric mean · (h*ug/ml)/(mg/m2)
Daunorubicinol Dose-normalized Plasma: AUC(0-t)
(h*ug/ml)/(mg/m2)Eltrombopag (ELQ) QDPlacebo QD
Daunorubicinol Dose-normalized Plasma: AUC(0-t)62.463 (57.268 to 68.129)61.608 (57.500 to 66.009)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Ratio of geometric means (%): 101.4 · 90% CI 92.4 to 111.2
SecondaryDaunorubicin Dose-normalized Plasma: AUC(24-t)

Daunorubicin AUC(24-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

Time frame:
Cycle 1 Day 4 to Day 9 (24 to 144 hrs post-dose)
Reported as:
Geometric mean · (h*ug/ml)/(mg/m2)
Daunorubicin Dose-normalized Plasma: AUC(24-t)
(h*ug/ml)/(mg/m2)Eltrombopag (ELQ) QDPlacebo QD
Daunorubicin Dose-normalized Plasma: AUC(24-t)0.76524 (0.65947 to 0.88797)0.59660 (0.48882 to 0.72813)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Ratio of geometric means (%): 120.0 · 90% CI 100.7 to 142.6
SecondaryDaunorubicinol Dose-normalized Plasma: AUC(24-t)

Daunorubicinol AUC(24-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

Time frame:
Cycle 1 Day 4 to Day 9 (24 to 144 hrs post-dose)
Reported as:
Geometric mean · (h*ug/ml)/(mg/m2)
Daunorubicinol Dose-normalized Plasma: AUC(24-t)
(h*ug/ml)/(mg/m2)Eltrombopag (ELQ) QDPlacebo QD
Daunorubicinol Dose-normalized Plasma: AUC(24-t)22.963 (20.557 to 25.651)21.821 (20.020 to 23.783)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Ratio of geometric means (%): 105.2 · 90% CI 93.6 to 118.3
SecondaryDaunorubicin Dose-normalized Plasma: Cmax

Daunorubicin Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

Time frame:
Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Reported as:
Geometric mean · (ug/ml)/(mg/m2)
Daunorubicin Dose-normalized Plasma: Cmax
(ug/ml)/(mg/m2)Eltrombopag (ELQ) QDPlacebo QD
Daunorubicin Dose-normalized Plasma: Cmax5.1527 (3.9561 to 6.7114)6.4113 (4.6773 to 8.7882)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Ratio of geometric means (%): 80.4 · 90% CI 57.2 to 113.0
SecondaryDaunorubicinol Dose-normalized Plasma: Cmax

Daunorubicinol Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

Time frame:
Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Reported as:
Geometric mean · (ug/ml)/(mg/m2)
Daunorubicinol Dose-normalized Plasma: Cmax
(ug/ml)/(mg/m2)Eltrombopag (ELQ) QDPlacebo QD
Daunorubicinol Dose-normalized Plasma: Cmax3.5770 (3.0433 to 4.2044)3.3640 (2.8433 to 3.9799)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Ratio of geometric means (%): 106.3 · 90% CI 87.6 to 129.0
SecondaryCycle 2: Daunorubicin Dose-normalized Plasma: AUC(0-24)

Cycle 2 Daunorubicin AUC(0-24). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

Time frame:
Cycle 2 Day 1 to Day 2 (0 to 24 post-dose)
Reported as:
Geometric mean · (h*ug/ml)/(mg/m2)
Cycle 2: Daunorubicin Dose-normalized Plasma: AUC(0-24)
(h*ug/ml)/(mg/m2)Eltrombopag (ELQ) QDPlacebo QD
Cycle 2: Daunorubicin Dose-normalized Plasma: AUC(0-24)10.315 (6.7932 to 15.662)8.1146 (6.0221 to 10.934)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Ratio of geometric means (%): 127.1 · 90% CI 84.2 to 191.9
SecondaryCycle 2: Daunorubicinol Dose-normalized Plasma: AUC(0-24)

Cycle 2 Daunorubicinol AUC(0-24). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

Time frame:
Cycle 2 Day 1 to Day 2 (0 to 24 post-dose)
Reported as:
Geometric mean · (h*ug/ml)/(mg/m2)
Cycle 2: Daunorubicinol Dose-normalized Plasma: AUC(0-24)
(h*ug/ml)/(mg/m2)Eltrombopag (ELQ) QDPlacebo QD
Cycle 2: Daunorubicinol Dose-normalized Plasma: AUC(0-24)34.067 (26.479 to 43.829)30.820 (24.148 to 39.335)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Ratio of geometric means (%): 110.5 · 90% CI 83.9 to 145.7
SecondaryCycle 2: Daunorubicin Dose-normalized Plasma: Cmax

Cycle 2 Daunorubicin Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

Time frame:
Cycle 2 Day 1 to Day 2 (0 to 24 post-dose)
Reported as:
Geometric mean · (ug/ml)/(mg/m2)
Cycle 2: Daunorubicin Dose-normalized Plasma: Cmax
(ug/ml)/(mg/m2)Eltrombopag (ELQ) QDPlacebo QD
Cycle 2: Daunorubicin Dose-normalized Plasma: Cmax11.141 (4.3653 to 28.432)3.8905 (1.2805 to 11.820)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Ratio of geometric means (%): 286.4 · 90% CI 90.1 to 910.7
SecondaryCycle 2: Daunorubicinol Dose-normalized Plasma: Cmax

Cycle 2 Daunorubicinol Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.

Time frame:
Cycle 2 Day 1 to Day 2 (0 to 24 post-dose)
Reported as:
Geometric mean · (ug/ml)/(mg/m2)
Cycle 2: Daunorubicinol Dose-normalized Plasma: Cmax
(ug/ml)/(mg/m2)Eltrombopag (ELQ) QDPlacebo QD
Cycle 2: Daunorubicinol Dose-normalized Plasma: Cmax4.0200 (2.5302 to 6.3870)1.9868 (1.4247 to 2.7708)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Ratio of geometric means (%): 202.3 · 90% CI 131.3 to 311.8
SecondaryNumber of Platelet Transfusions Per Week Within Cycles

This was the average number of platelet transfusions per week within cycles.

Time frame:
Post-Base line up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Reported as:
Median · Platelet transfusions per week
Number of Platelet Transfusions Per Week Within Cycles
Platelet transfusions per weekEltrombopag (ELQ) QDPlacebo QD
Number of Platelet Transfusions Per Week Within Cycles1.5 ± 1.181.4 ± 1.22
SecondaryTime to Platelet Count Recovery >=20 Gi/L

Time to Platelet counts \>= 20 Gi/L for 3 consecutive days, unaided by transfusions in patients with \< 20 Gi/L after chemotherapy. For this endpoint, the event required platelet count to be \>= 20 Gi/L for 3 consecutive days. Hematology was assessed daily during hospital stay but only weekly after hospital discharge and thus, platelet count was not always available for 3 consecutive days to confirm the achievement of platelet count recovery.

Time frame:
From last dose of chemotherapy to up to end of study year 2 assessment
Reported as:
Median · Months
Time to Platelet Count Recovery >=20 Gi/L
MonthsEltrombopag (ELQ) QDPlacebo QD
Time to Platelet Count Recovery >=20 Gi/LNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Log Rank · p = 0.7461 · Hazard ratio (hr): 0.84 · 95% CI 0.28 to 2.48
SecondaryTime to Platelet Recovery >=100 Gi/L

Time to platelet counts \>= 100 Gi/L unaided by transfusions in participants with \< 100 Gi/L after chemotherapy.

Time frame:
From last dose of chemotherapy to up to end of study year 2 assessment
Reported as:
Median · Months
Time to Platelet Recovery >=100 Gi/L
MonthsEltrombopag (ELQ) QDPlacebo QD
Time to Platelet Recovery >=100 Gi/L0.69 (0.69 to 0.76)0.69 (0.69 to 0.82)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Log Rank · p = 0.6175 · Hazard ratio (hr): 1.10 · 95% CI 0.74 to 1.63
SecondaryNumber of Participants Who Achieved Platelet Count Recovery by Day 21

Number of participants with platelet counts 20 Gi/L for 3 consecutive days, unaided by transfusions, in patients with \< 20 Gi/L after chemotherapy.

Time frame:
By Day 21
Reported as:
Number · Count of participants
Number of Participants Who Achieved Platelet Count Recovery by Day 21
Count of participantsEltrombopag (ELQ) QDPlacebo QD
Number of Participants Who Achieved Platelet Count Recovery by Day 2147
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Cochran-Mantel-Haenszel · p = 0.3224 · Odds ratio (or): 0.5281 · 95% CI 0.1084 to 2.2086
SecondarySummary of Platelet Counts Over Time

Platelet counts over time

Time frame:
Baseline, daily then weekly within cycle up to 42 days after last chemotherapy dose, end of therapy /remission assessment visit
Reported as:
Median · Gi/L
Summary of Platelet Counts Over Time
Gi/LEltrombopag (ELQ) QDPlacebo QD
Baseline51.5 (5 to 241)50.0 (9 to 232)
C1D152.0 (5 to 241)48.5 (9 to 232)
C1D243.5 (4 to 237)42.0 (5 to 368)
C1D335.5 (4 to 226)37.0 (7 to 220)
C1D436.5 (3 to 227)29.0 (5 to 146)
C1D533.0 (3 to 201)29.0 (5 to 146)
C1D632.0 (4 to 164)30.0 (6 to 125)
C1D727.0 (3 to 123)27.0 (4 to 102)
C1D824.0 (2 to 99)22.0 (4 to 80)
C1D920.5 (1 to 109)19.0 (5 to 59)
C1D1416.5 (0 to 70)18.0 (1 to 81)
C1D2139.0 (5 to 325)25.0 (2 to 232)
C1D28484.5 (14 to 1590)121.0 (7 to 539)
C1D35547.0 (15 to 1493)181.0 (10 to 424)
C1D42—304.0 (304 to 304)
C2D131.0 (12 to 1059)30.5 (10 to 432)
C2D226.0 (3 to 831)28.5 (8 to 400)
C2D325.5 (0 to 730)29.0 (8 to 437)
C2D432.0 (2 to 678)35.5 (11 to 454)
C2D537.0 (9 to 516)22.0 (12 to 476)
C2D627.0 (4 to 430)33.0 (7 to 533)
C2D724.0 (6 to 295)28.5 (12 to 390)
C2D1410.5 (3 to 31)16.0 (6 to 66)
C2D2127.0 (9 to 86)38.0 (8 to 141)
C2D2868.0 (48 to 333)173.0 (32 to 479)
C2D35515.0 (412 to 618)272.0 (26 to 329)
C2D42—147.5 (45 to 250)
SecondaryMaximum Duration (Days) of Platelet Transfusion Independence

Maximum time period (in days) during which the patient did not receive any platelet transfusion

Time frame:
At differnt time points from start of treatment and up to end of study year 2 assessment
Reported as:
Median · Days
Maximum Duration (Days) of Platelet Transfusion Independence
DaysEltrombopag (ELQ) QDPlacebo QD
Maximum Duration (Days) of Platelet Transfusion Independence29.0 (2 to 57)29.5 (2 to 77)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Wilcoxon rank-sum test · p = 0.6942
SecondaryPercentage of Patients Who Achieved Platelet Transfusion Independence ≥ 28 Days

Percentage of patients who achieved platelet transfusion independence ≥ 28 days.

Time frame:
From start of treatment and up to end of study year 2 assessment
Reported as:
Number · Percentage of participants
Percentage of Patients Who Achieved Platelet Transfusion Independence ≥ 28 Days
Percentage of participantsEltrombopag (ELQ) QDPlacebo QD
Percentage of Patients Who Achieved Platelet Transfusion Independence ≥ 28 Days5553
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Cochran-Mantel-Haenszel · p = 0.7397 · Odds ratio (or): 1.1151 · 95% CI 0.5585 to 2.2290
SecondaryTime to Neutrophil Engraftment

Time to absolute neutrophil count (ANC) \>= 0.5 Gi/L for 3 consecutive days in participants with ANC \< 0.5 Gi/L after chemotherapy

Time frame:
At different time points from last dose of chemotherapy up to end of study year 2 assessment
Reported as:
Median · Months
Time to Neutrophil Engraftment
MonthsEltrombopag (ELQ) QDPlacebo QD
Time to Neutrophil EngraftmentNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Log Rank · p = 0.0781 · Hazard ratio (hr): 2.46 · 95% CI 0.95 to 6.38
SecondarySummary of Absolute Neutrophil Counts (ANC)

Absolute neutrophil counts over time

Time frame:
Baseline, daily then weekly within cycle up to 42 days after last chemotherapy dose, end of therapy /remission assessment visit
Reported as:
Median · Gi/L
Summary of Absolute Neutrophil Counts (ANC)
Gi/LEltrombopag (ELQ) QDPlacebo QD
Baseline0.8 (0 to 37)0.5 (0 to 50)
C1D10.8 (0 to 37)0.6 (0 to 50)
C1D20.6 (0 to 41)0.5 (0 to 41)
C1D30.6 (0 to 59)0.4 (0 to 26)
C1D40.4 (0 to 35)0.2 (0 to 17)
C1D50.3 (0 to 21)0.2 (0 to 2)
C1D60.2 (0 to 35)0.1 (0 to 1)
C1D70.1 (0 to 29)0.1 (0 to 1)
C1D80.1 (0 to 21)0.0 (0 to 1)
C1D90.0 (0 to 7)0.0 (0 to 1)
C1D140.0 (0 to 1)0.0 (0 to 0)
C1D210.6 (0 to 18)0.3 (0 to 7)
C1D284.3 (0 to 47)2.7 (0 to 25)
C1D352.2 (0 to 56)1.7 (0 to 12)
C1D42—3.1 (3.1 to 3.1)
C2D10.1 (0 to 7)0.0 (0 to 5)
C2D20.1 (0 to 3)0.2 (0 to 4)
C2D30.2 (0 to 5)0.5 (0 to 4)
C2D40.3 (0 to 3)0.5 (0 to 2)
C2D50.2 (0 to 2)0.1 (0 to 3)
C2D60.1 (0 to 1)0.1 (0 to 3)
C2D70.0 (0 to 1)0.1 (0 to 2)
C2D140.0 (0 to 0)0.0 (0 to 0)
SecondarySummary of Hemoglobin

Hemoglobin level over time

Time frame:
Baseline, daily then weekly within cycle up to 42 days after last chemotherapy dose, end of therapy /remission assessment visit
Reported as:
Median · g/L
Summary of Hemoglobin
g/LEltrombopag (ELQ) QDPlacebo QD
Baseline87.6 (63 to 123)87.0 (67 to 121)
C1D188.0 (67 to 123)86.0 (67 to 121)
C1D288.0 (58 to 124)83.0 (62 to 130)
C1D386.0 (52 to 108)82.0 (59 to 130)
C1D483.0 (60 to 105)81.5 (46 to 120)
C1D584.0 (60 to 114)83.0 (50 to 126)
C1D686.0 (67 to 118)82.0 (52 to 119)
C1D785.0 (58 to 116)83.0 (57 to 110)
C1D885.3 (65 to 118)84.0 (57 to 108)
C1D984.5 (64 to 114)81.5 (62 to 109)
C1D1485.0 (60 to 123)84.0 (59 to 109)
C1D2188.0 (77 to 117)88.0 (72 to 116)
C1D2899.0 (78 to 138)98.0 (79 to 125)
C1D3599.0 (81 to 131)94.0 (74 to 130)
C1D42—98.0 (98 to 98)
C2D194.5 (76 to 124)82.5 (72 to 111)
C2D288.5 (72 to 112)86.5 (69 to 104)
C2D386.5 (65 to 110)80.0 (68 to 97)
C2D489.0 (72 to 106)86.5 (74 to 109)
C2D588.0 (67 to 101)84.0 (72 to 93)
C2D684.0 (68 to 102)85.0 (70 to 96)
C2D784.5 (66 to 99)83.0 (57 to 97)
C2D1477.5 (66 to 101)87.0 (79 to 96)
C2D2186.0 (43 to 99)91.0 (74 to 110)
C2D2889.0 (80 to 92)80.0 (72 to 114)
C2D35104.0 (101 to 107)87.0 (85 to 119)
C2D42—90.5 (86 to 95)
SecondaryIncidence of Hemorrhagic Events

Incidence of bleeding events using WHO bleeding grade (G0=No bleeding, G1=Petechiae, G2=Mild blood loss, G3=Gross blood loss, G4=Debilitating blood loss) by week and cycle

Time frame:
Baseline, weekly within induction and re-induction cycles, end of therapy
Reported as:
Number · Participants
Incidence of Hemorrhagic Events
ParticipantsEltrombopag (ELQ) QDPlacebo QD
C1D7 - GRADE 05847
C1D7 - GRADE 1916
C1D7 - GRADE 256
C1D7 - GRADE 310
C1D14 - GRADE 04243
C1D14 - GRADE 11613
C1D14 - GRADE 256
C1D14 - GRADE 310
C1D21 - GRADE 03643
C1D21 - GRADE 1137
C1D21 - GRADE 231
C1D21 - GRADE 301
C1D28 - GRADE 03125
C1D28 - GRADE 143
C1D28 - GRADE 220
C1D28 - GRADE 300
C1D35 - GRADE 01211
C1D35 - GRADE 122
C1D35 - GRADE 200
C1D35 - GRADE 300
C1D42 - GRADE 0—0
C1D42 - GRADE 1—1
C1D42 - GRADE 2—0
C1D42 - GRADE 3—0
C2D1 - GRADE 088
C2D1 - GRADE 114
C2D1 - GRADE 210
C2D1 - GRADE 300
C2D7 - GRADE 098
C2D7 - GRADE 103
C2D7 - GRADE 210
C2D7 - GRADE 300
C2D14 - GRADE 087
C2D14 - GRADE 103
C2D14 - GRADE 200
C2D14 - GRADE 300
C2D21 - GRADE 077
C2D21 - GRADE 112
C2D21 - GRADE 200
C2D21 - GRADE 300
C2D28 - GRADE 057
C2D28 - GRADE 101
C2D28 - GRADE 200
C2D28 - GRADE 300
C2D35 - GRADE 032
C2D35 - GRADE 101
C2D35 - GRADE 200
C2D35 - GRADE 300
C2D42 - GRADE 0—0
C2D42 - GRADE 1—1
C2D42 - GRADE 2—0
C2D42 - GRADE 3—0
Remission visit GRADE 05658
Remission visit GRADE 124
Remission visit GRADE 230
Remission visit GRADE 310
SecondaryPercentage of Participants With Disease Response Rate and Type of Response

Disease response as assessed by the investigator using the AML International Working Group Response Assessment at the end of therapy/remission assessment visit; Complete remission (CR): defined as transfusion independence, blood count recovery (Abs. neutrophil count \> 1.0 Gi/L and Platelet count \> 100.0 Gi/L), no leukemic blast in peripheral blood, Bone Marrow (BM) blasts \< 5%, maturation of all cell lines, Auer rods not detectable, and no extramedullary disease. Partial remission (PR): defined as CR except that for BM blasts where a decrease of at least 50% of BM blasts to 5-25% in BM aspirate is sufficient or BM blasts \< 5% with Auer rods present. Overall response (OR) = CR + PR.

Time frame:
Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Response Rate and Type of Response
Percentage of participantsEltrombopag (ELQ) QDPlacebo QD
Overall response7073
Complete Remission (CR)6570
Partial Remission (PR)53
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Cochran-Mantel-Haenszel · p = 0.7122 · Odds ratio (or): 0.8749 · 95% CI 0.4023 to 1.8943
SecondaryOverall Survival (OS)

Overall survival defined as the time form randomization until the date of death due to any cause.

Time frame:
From randomization to end of 2-year follow-up
Reported as:
Number · Count of participants
Overall Survival (OS)
Count of participantsEltrombopag (ELQ) QDPlacebo QD
Overall Survival (OS)3930
Statistical analysis
  • Eltrombopag (ELQ) QD vs Placebo QD · Log Rank · p = 0.0688 · Hazard ratio (hr): 1.54 · 95% CI 0.96 to 2.47
SecondaryNumber of Participants Who Required Medical Resource Utilization

Medical Resource Utilization pertained to unscheduled hospitalizations, unscheduled office visits, unscheduled laboratory tests, and unscheduled procedures.

Time frame:
At screening and from start of treatment to end of therapy/remission assessment visit (Day 42 of the latest chemotherapy cycle)
Reported as:
Number · Count of participants
Number of Participants Who Required Medical Resource Utilization
Count of participantsEltrombopag (ELQ) QDPlacebo QD
In-patient hospitalizations/ admissions?34
Diagnostic imaging procedures performed?34
Health care resources use or emergency visits?86
Out-patient lab tests performed?66

Adverse events

Collected over Adverse events and serious adverse events were collected from Day 1 of cycle 1 until last dose of investigational product + 30 days i.e. a maximum of 114 days (42 days for the induction cycle + 42 days for the re-induction cycle + 30 days for the follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag (ELQ) QD11/74 (14.9%)24/74 (32.4%)71/74 (95.9%)
Placebo QD4/71 (5.6%)14/71 (19.7%)66/71 (93%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventEltrombopag (ELQ) QDPlacebo QD
Acute kidney injuryRenal and urinary disorders3/741/71
SepsisInfections and infestations1/742/71
Septic shockInfections and infestations2/742/71
Ejection fraction decreasedInvestigations0/742/71
Atrial fibrillationCardiac disorders2/740/71
Haemorrhage intracranialNervous system disorders2/740/71
Cardiac failureCardiac disorders1/741/71
Cardiac failure congestiveCardiac disorders0/741/71
CardiomyopathyCardiac disorders0/741/71
ConstipationGastrointestinal disorders0/741/71
Most frequent other events
Showing 10 of 96
Most frequent other events
EventEltrombopag (ELQ) QDPlacebo QD
NauseaGastrointestinal disorders37/7446/71
DiarrhoeaGastrointestinal disorders42/7443/71
Febrile neutropeniaBlood and lymphatic system disorders38/7442/71
VomitingGastrointestinal disorders27/7427/71
Decreased appetiteMetabolism and nutrition disorders22/7427/71
HypokalaemiaMetabolism and nutrition disorders20/7427/71
ConstipationGastrointestinal disorders28/7421/71
PyrexiaGeneral disorders25/7417/71
InsomniaPsychiatric disorders16/7423/71
RashSkin and subcutaneous tissue disorders22/7413/71

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Eltrombopag (ELQ) QDPlacebo QDTotal
Mean56.7 ± 12.2556.6 ± 11.5856.7 ± 11.88
Sex: Female, Male
Sex: Female, Male(Participants)Eltrombopag (ELQ) QDPlacebo QDTotal
Female383169
Male364379
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Eltrombopag (ELQ) QDPlacebo QDTotal
African American/African Heritage123
Asian - Central/South Asian Heritage011
Asian - East Asian Heritage261743
Asian - South East Asian Heritage011
White - Arabic/North African Heritage538
White - White/Caucasian/European Heritage425092
08

Study locations

42 sites
  • Novartis Investigative Site
    Farmington, Connecticut 06030-1628, United States
  • Novartis Investigative Site
    Miami, Florida 33136, United States
  • Novartis Investigative Site
    Orlando, Florida 32806, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30322, United States
  • Novartis Investigative Site
    Ames, Iowa 50010, United States
  • Novartis Investigative Site
    Sioux City, Iowa 51101-1733, United States
  • Novartis Investigative Site
    Burlington, Massachusetts 01805, United States
  • Novartis Investigative Site
    Kansas City, Missouri 64128, United States
  • Novartis Investigative Site
    Rochester, New York 14642, United States
  • Novartis Investigative Site
    Durham, North Carolina 22713, United States
  • Novartis Investigative Site
    Canton, Ohio 44710, United States
  • Novartis Investigative Site
    Philadelphia, Pennsylvania 19104, United States
  • Novartis Investigative Site
    Providence, Rhode Island 02903, United States
  • Novartis Investigative Site
    Nashville, Tennessee 37232, United States
  • Novartis Investigative Site
    Kogarah, New South Wales 2217, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3004, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3050, Australia
  • Novartis Investigative Site
    Bruxelles, 1070, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Montreal, Quebec H2L 4M1, Canada
  • Novartis Investigative Site
    Athens, 11527, Greece
  • Novartis Investigative Site
    Patra, 26500, Greece
  • Novartis Investigative Site
    Debrecen, 4012, Hungary
  • Novartis Investigative Site
    Szeged, 6720, Hungary
  • Novartis Investigative Site
    Haifa, 31096, Israel
  • Novartis Investigative Site
    Holon, 58100, Israel
  • Novartis Investigative Site
    Jerusalem, 91031, Israel
  • Novartis Investigative Site
    Jerusalem, 91120, Israel
  • Novartis Investigative Site
    Kfar Saba, 44281, Israel
  • Novartis Investigative Site
    Tel-Aviv, 64239, Israel
  • Novartis Investigative Site
    Seoul, Korea, 137-701, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 135-710, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 138-736, Korea, Republic of
  • Novartis Investigative Site
    Slupsk, 76-200, Poland
  • Novartis Investigative Site
    Wroclaw, 50-367, Poland
  • Novartis Investigative Site
    Kaluga, 248007, Russian Federation
  • Novartis Investigative Site
    Moscow, 115478, Russian Federation
  • Novartis Investigative Site
    Nizhniy Novgorod, 603126, Russian Federation
  • Novartis Investigative Site
    Penza, 440071, Russian Federation
  • Novartis Investigative Site
    St'Petersburg, 197341, Russian Federation
  • Novartis Investigative Site
    Tula, 300053, Russian Federation
09

References and documents

Publications

  • Frey N, Jang JH, Szer J, Illes A, Kim HJ, Ram R, Chong BH, Rowe JM, Borisenkova E, Liesveld J, Winer ES, Cherfi A, Aslanis V, Ghaznawi F, Strickland S. Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. Lancet Haematol. 2019 Mar;6(3):e122-e131. doi: 10.1016/S2352-3026(18)30231-X. Epub 2019 Jan 29. PubMed 30704923 ↗

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Mar 2015, 18 months.

Results were first posted in Jun 2016, 1 year 3 months after primary completion.

Of 32 industry-sponsored phase 2 interventional studies under Leukemia, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 61. This study's 18 months is below that.

Counting every sponsor, half of 176 studies reached it within 76 months; a quarter within 44 and three quarters within 123.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2013
First posted
Jul 2, 2013
StartActual
Sep 5, 2013
Primary completionActual
Mar 13, 2015
CompletionActual
Jan 25, 2017
Results first posted
Jun 14, 2016
Last update
Sep 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01890746
Responsible party
Sponsor
First posted
Jul 2, 2013
Start date
Sep 5, 2013
Primary completion
Mar 13, 2015
Completion
Jan 25, 2017
Results posted
Jun 14, 2016
Last update
Sep 11, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion